Navigation Links
Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine
Date:9/15/2009

Expressionist modules Refiner Array and Analyst deliver expanded processing and reporting functionalities.

Basel, Switzerland and Lexington, MA (PRWEB), September 15, 2009 -- Genedata, a leading provider of in silico solutions for pharmaceutical R&D and related life sciences, today announced the release of Genedata Expressionist® 5.3 with enhanced capabilities for transcriptomics-based biomarker discovery for applications in drug profiling and patient selection.

"Expressionist can analyze large amounts of data with highly sophisticated statistical features, not only to visualize your data but also to pre-process them, perform classical statistical analysis, and very high-end classification and prediction," said Dr. Sergio Baranzini, Associate Professor in the Department of Neurology at the University of California San Francisco. Baranzini's team is part of an academic research consortium studying the genetics of multiple sclerosis. "We tested the breadth of software possibilities and Genedata Expressionist goes beyond the capabilities of most software I've ever worked with," continued Baranzini. "Expressionist's intuitive nature eliminates the trial-and-error process that usually can't be avoided when working with analytical software."

Expressionist 5.3 expands the process capabilities of its Refiner Array module to support the next generation of microarrays, including Affymetrix Whole-Transcript and Exon arrays. In response to the growing importance of customized arrays, flexibility in pre-processing raw data has been increased by incorporating array type-specific layout information. Furthermore, data quality assessment functionality as well as access to biological information has been significantly enhanced. To support automated workflow-based SOPs for applications in personalized medicine, a completely new reporting engine has been developed. Processing performance has also been optimized to enable efficient analysis of large-scale microarray projects.

"The release of Expressionist 5.3 is another major step in supporting high-performance data processing and accurate data analysis of the large-scale microarray projects that are becoming standard in drug discovery and related life science applications," noted Dr. Othmar Pfannes, CEO of Genedata. Recent Expressionist releases have already augmented technology support in transcriptomics, proteomics and metabolomics as well as enabled high-end cross-omics data processing for mass spectrometry and transcriptomics data.

"Genedata is committed to supporting novel technologies and providing innovative solutions to meet the needs of our users and the demands of constantly evolving technologies," continued Dr. Pfannes. "As an independent company with a proven track record of delivering best-in-class services to customers around the world, we look forward to collaborating with our partners to improve the efficiency of drug discovery and development in the life sciences."

About Genedata
Genedata develops and globally markets sophisticated computational solutions for drug discovery and related research processes in the life sciences. Genedata's solutions enable scientists to process, integrate, analyze, and manage large and complex experimental data sets generated by high throughput technologies. Solutions include Genedata Phylosopher® for target discovery and integrative biological data management, Genedata Screener® for automated high throughput screening and high content screening, and Genedata Expressionist® for biomarker discovery and personalized medicine. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Boston & San Francisco, USA, Konstanz & Munich, Germany and Tokyo, Japan. For more information, please visit www.genedata.com.

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

###

Read the full story at http://www.prweb.com/releases/Genedata/Expressionist/prweb2878464.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities
2. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
3. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
4. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
5. Ingenuity Systems Joins Biomarkers Consortium
6. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
7. Decision Biomarkers Launches System for Faster, Easier Quantification of Protein Biomarkers
8. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
9. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
10. Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project
11. Genetic Engineering & Biotechnology News reports on cancer biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election in November and the ... will bring together over 500 top healthcare leaders for a night and day of ... organized by MBA students of the University of Pennsylvania’s Wharton School, will be held ...
(Date:2/9/2016)... PA (PRWEB) , ... February 09, 2016 , ... Tunnell ... Europe. Based in Paris, he will focus on acquiring new accounts and work ... met. , “Fred brings to our European clients more than 15 ...
(Date:2/9/2016)... This market research report on the global ... of the market in terms of revenue (USD Million). ... the manufacture of microbiology culture media and related products. ... snapshot providing the overall information of various market segments ... also provides the overall information and data analysis of ...
(Date:2/8/2016)... , Feb. 8, 2016 /PRNewswire/ - BIOREM Inc. (TSXV: ... the top ten finalists for clean technology companies in the ... the top 10 companies listed on the TSX Venture Exchange, ... & gas, clean technology & life sciences, diversified ... equal weighting given to return on investment, market cap growth, ...
Breaking Biology Technology:
(Date:2/4/2016)... , Feb. 4, 2016 The ... apparently one of the most popular hubs of ... MetaHIT and other huge studies of human microbiota, ... past few years, the microbiome space has literally ... biomedical research. This report focuses on biomedical ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS devices ... primarily focused on medical screening and diagnostic ... parameters. Wearable devices that facilitate and assure ... of movement are being bolstered through new ... biomedical signal acquisition coupled with wireless connectivity ...
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
Breaking Biology News(10 mins):